1. Introduction {#sec1}
===============

Cancer is among the most common causes of mortality worldwide and the second leading death cause in the United States.^[@ref1]^ According to cancer statistics reported in 2020 by the American Cancer Society, prostate cancer is the leading cancer type with estimated new cases and the second with estimated cancer deaths in the US in 2020.^[@ref1]^ Despite continuing efforts for the development of anticancer agents, the current cancer therapeutic modalities are still limited because of accompanied side effects and development of drug resistance.^[@ref2]^ Thus, identifying novel effective therapies for various types of cancers is a continuing focus of medical research.

In the last two decades, the basis of cancer evolution has been tackled on the molecular basis, allowing the characterization of a plethora of key cellular components involved in carcinogenesis. Among these cellular components are protein kinases, which can trigger tumorigenesis when mutated or overly expressed. Protein kinases play a pivotal role in nearly all cellular functions through controlling metabolism, transcription, cell division, movement, survival, signaling, and programmed cell death.^[@ref3]^ They transfer a γ phosphate group from an ATP molecule to substrate proteins by catalyzing the reaction of adding a phosphate group into a nucleophilic amino acid in the presence of an Mg^2+^ ion.^[@ref4]^ In general, they fall, according to the amino acid being phosphorylated, into four main groups, tyrosine kinases (TKs), serine/threonine kinases (STKs),^[@ref3]^ dual specificity kinases, which phosphorylate both serine/threonine and tyrosine amino acids,^[@ref5]^ and histidine kinases.^[@ref6]^ Kinases, together with phosphatases, control over the reversible protein phosphorylation process, in which any unbalance leads to various disease states.^[@ref3],[@ref7],[@ref8]^ Impaired kinase activity results in uncontrolled cell proliferation, which is common in cancer.^[@ref9]^ Because of its involvement in many diseases including cancer, this enzyme family has become one of the most important drug targets in the 21st century.^[@ref8]^

Glycogen synthase kinase-3 (GSK-3), an enzyme that was reported in late 1970s, was known to regulate glycogen synthase; hence, its name was driven.^[@ref10]−[@ref12]^ Later on, it was found to modulate several other cellular activities by phosphorylating over 100 protein targets making it the busiest kinase.^[@ref13]^ GSK-3 is a poly functional STKs that exists in two isoforms, GSK-3α and GSK-3β, which share a high degree of similarity within their active kinase domain.^[@ref11]^ GSK-3β is implicated in many age-related disorders such as diabetes,^[@ref14]^ Alzheimer's disease,^[@ref15]^ bipolar disorder,^[@ref16]^ inflammation,^[@ref17]^ cardiovascular diseases,^[@ref18]^ and cancer.^[@ref19]^ The role of GSK-3β in cancer is paradoxical as it is reported to serve as either a tumor suppressor or tumor promoter.^[@ref20]^ It is reported to be a tumor suppressor in breast,^[@ref21]−[@ref23]^ lung,^[@ref24],[@ref25]^ oral,^[@ref26],[@ref27]^ and skin^[@ref28],[@ref29]^ cancers, and tumor promoter in prostate,^[@ref30]^ colorectal,^[@ref31],[@ref32]^ glioblastoma multiforme,^[@ref33],[@ref34]^ renal,^[@ref35]^ pancreas,^[@ref36]−[@ref39]^ leukemia,^[@ref40],[@ref41]^ and hepatocellular carcinoma,^[@ref42],[@ref43]^ through inhibition of autophagy mediated by activation of mammalian target of rapamycin complex-1 (mTORC1) activity.^[@ref44]^

GSK-3β is upregulated in androgen receptor (AR)-dependent prostate cancer.^[@ref30]^ Inhibition of GSK-3β has been found to suppress prostate cancer cells proliferation in vitro^[@ref45]−[@ref49]^ and tumor growth in xenograft in vivo.^[@ref50]^ Inhibitors of GSK-3β that have reached clinical trials are summarized in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A.^[@ref51]^ Among the reported inhibitors, it was found that many possess fused 5--6-membered heterocyclic ring systems^[@ref52],[@ref53]^ (**I--III**, [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B).

![(A) Representative GSK-3β inhibitors under clinical trials, (B) GSK-3 inhibitors having 5--6-fused ring system (**I--III**) including our discovered triazolothiadiazine (**5l**).](ao0c01829_0002){#fig1}

Triazolothiadiazine-based scaffolds possess versatile medicinal uses^[@ref54]^ such as antimicrobial,^[@ref55]^ anti-inflammatory,^[@ref56]^ antitubercular,^[@ref57]^ and anticancer agents.^[@ref58]−[@ref72]^ Triazolothiadiazine-based scaffolds ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B) bear some common structural features with the 5--6-membered fused ring system GSK3B inhibitors.

In this work, structure--activity relationship (SAR) of triazolothiadiazine compounds with reported anticancer activity is generated to give insights into the design of our novel hydrazinotriazolothiadiazine kinase inhibitor analogues. Thus, a series of disubstituted hydrazinotriazolothiadiazine analogues were synthesized and biologically assessed on NCI-60 cell lines. Among the tested compounds, **5l** was found to possess potential GSK-3β inhibitory activity through target fishing and kinase screening.

2. Results and Discussion {#sec2}
=========================

2.1. Rational Design Based on SAR of Reported Anticancer Triazolothiadiazines {#sec2.1}
-----------------------------------------------------------------------------

By looking at the reported anticancer triazolothiadiazines, general structural features can be concluded ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). The fused 5--6-membered ring system is essential for activity. The unfused 5-membered ring systems were found to be inactive.^[@ref58]−[@ref60]^ The 3-Mercapto-oxadiazole (**IV**, [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"})^[@ref60]^ and the 3-mercapto-4-amino-(1,2,4)-triazole (**V**, [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"})^[@ref58]−[@ref60]^ are reported to be inactive. Unsaturation of the thiadiazine ring appears to be important for activity, as the saturated derivative was reported to be inactive (**VI**, [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}).^[@ref61]^ Aromatic substitution at position 3 of the triazole ring is connected through a spacer with varied length of zero,^[@ref62]−[@ref66]^ one,^[@ref58],[@ref59]^ two,^[@ref67]^ or three^[@ref58],[@ref61],[@ref68]−[@ref70]^ atoms. The 3-atom spacer showed better activity. Aromatic substitution at 6-position of the triazolothiadiazine ring showed superior activity over the aliphatic counterparts. Halogeno-substituted aryls, especially with chlorine,^[@ref61]−[@ref63],[@ref65]−[@ref68],[@ref70]^ were better with regard to activity than other electron-donating groups, as aliphatic substitution demolished the compounds' anticancer activity.^[@ref68]^ Substitution at position 7 of the triazolothiadiazine ring can be important for activity, but not essential;^[@ref71]^ in addition, it can be utilized for blocking metabolic oxidation of thioether.^[@ref61]^

![General SAR for triazolothiadiazine analogues possessing anticancer/antitumor activity.](ao0c01829_0003){#fig2}

In our design, we kept the fused 5--6 triazolothiadiazine unsaturated ring system which is essential for activity. In position 3 of the triazolothiadiazine, we kept the three-atom spacer represented by an arylidene hydrazone and varied the aryl moiety with substituents of diverse steric, electronic, and polar properties. In position 6 of the triazolothiadiazine, a phenyl or 4-chloro-phenyl was kept.

2.2. Chemistry {#sec2.2}
--------------

The synthesis of target compounds **5** is shown in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}. The synthesis of compound **5a** was attempted as a one-pot reaction of equimolar amounts of purpald **1**, 2-bromoacetophenone **2a** and benzaldehyde **4a** in refluxing absolute ethanol and few drops of glacial acetic acid as reported by Thirupaiah and Vedula;^[@ref72]^ however, inspite of the consumption of the starting materials as monitored by thin-layer chromatography (TLC), the target compound was not attained with appropriate degree of purity and was obtained in poor yields.

![Reagents and conditions: (a) HCl, EtOH, H~2~O, reflux 1 h, 70--80%; (b) EtOH, reflux 2 h, 85--92%.](ao0c01829_0015){#sch1}

The lack of efficient methodology for synthesis of compounds **5** prompted us to do the reaction in a stepwise fashion through the stepwise synthesis of the hydrazino intermediate **3** followed by reaction with the corresponding aldehyde. This would allow us to have higher purity and yields of the final compounds. As, to the best of our knowledge, there was no literature precedence for the synthesis of intermediate **3**, it was decided to develop synthetic methodology toward these compounds taking into account that the nucleophilicity of sulfhydryl, amino, and hydrazino groups are very close. Attempts to react **1** and **2a** in refluxing ethanol in the absence of base, presence of NaOH, Na~2~CO~3~, or acetic acid resulted in a mixture of products that were difficult to purify. Dickinson and Jacobsen^[@ref73]^ selectively reacted benzaldehyde at the amino group of purpald in very good yield by dissolving purpald in 1 M HCl and adding benzaldehyde dissolved in ethanol over 10 min, and the reaction was left stirring for further 10 min. Applying the same methodology using phenacylbromide successfully afforded the desired product **3a** in very good yield (80%). The same reaction conditions also gave **3b** in 79% yield. With intermediate **3** in hand, we proceeded toward the synthesis of target compounds **5** which were easily prepared in excellent yields (83.1--91.5%) through the reaction of the appropriate aldehyde and intermediates **3**.

Refluxing a mixture of **3** and an aldehyde **4** in ethanol while monitoring the reaction progress by TLC effectively yielded the desired conversion in 2 h. The reaction mixture was then cooled to room temperature and quenched with Na~2~CO~3~ solution. The crude precipitate formed was filtered, washed with water, dried, and recrystallized from appropriate organic solvent.

The Fourier transform infrared (FTIR) spectra of the hydrochloride salts of compounds **3a** and **3b** showed broad peaks in the 3500--2500 cm^--1^. This peak disappeared after the coupling of **3a** and **3b** with aldehyde.

2.3. Biological Evaluation {#sec2.3}
--------------------------

### 2.3.1. In Vitro Antiproliferative Screening against NCI-60 Cell Lines {#sec2.3.1}

All twenty synthesized compounds (**5a--t**) were screened by the National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA (<https://dtp.cancer.gov/compsub/>)^[@ref74]^ under the Developmental Therapeutic Program (DTP) against NCI-60 human tumor cell lines. Compounds screened with respective NCI codes **NSC-809289**, **NSC-809281**, **NSC-809280**, **NSC-809286**, **NSC-809284**, **NSC-809285**, **NSC-809288**, **NSC-809282**, **NSC-809287**, **NSC-809283**, **NSC-809290**, **NSC-806976**, **NSC-806975**, **NSC-806979**, **NSC-806978**, **NSC-809292**, **NSC-809294**, **NSC-809291**, **NSC-809293**, and **NSC-806977** were tested for determination of percent inhibition of the full NCI-60 cell panel at a concentration of 10 μM. The compounds showed moderate inhibitory activity except for compound **5l** which showed the highest percent inhibition over the 60 cell lines with mean growth inhibition percentage of 45.44% ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}) ([Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c01829/suppl_file/ao0c01829_si_001.pdf)).

![Heat map depicting the growth inhibition percentage of the compounds **5a--t** (*y*-axis) at concentration of 10 μM against the NCI-60 cell lines (*x*-axis).](ao0c01829_0004){#fig3}

The series of the compounds with *p*-choloro substitution (**5k--t**) is more active than the unsubstituted series (**5a--j**), an observation consistent with our derived SAR of the reported triazolothiadiazine anticancer agents ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). This observation is consistent over the whole series except for the compounds with biphenyl hydrazone compounds, where the compound with the unsubstituted phenyl ring at position 6 (**5f**) is more active than the *p*-cholro substituted congenere (**5p**).

Concerning the phenyl ring of the hydrazinyl substitution at position 3 of the triazolothiadiazine ring, its unsubstitution (**5a** and **5k**), its substitution with *p*-phenyl (**5f** and **5p**), or replacement with 2-furyl (**5h** and **5r**) or 3-thiophenyl (**5i** and **5s**) rings rendered the compounds inactive as concluded from their mean percent inhibition, which are the least when compared to the rest of the series (**5b--e**, **5g**, **5j**, **5l--o**, **5q**, and **5t**). On the other hand, substitution of the phenyl ring generally enhances anticancer activity, especially with *p*-CF~3~ (**5l**) which dramatically increased the activity especially in RXF 393, UO-31, MCF7, and PC-3 cell lines.

**5l** showed 83.63, 96.48, and 79.34% inhibition on NSCLC HOP-62, HOP-92, and NCI-H226 cell lines, respectively. Moreover, it showed 79.74 and 124.92% inhibition on CNS SNB-19 and SNB-75 cell lines, respectively. Also, it showed 83.65, 82.61, 80.14, 96.96, and 91.7% inhibition on melanoma MALME-3M, ovarian OVCAR-4, ovarian OVCAR-8, renal RXF 393, and breast HS 578T cell lines, respectively. On renal cancer cell lines, its inhibition percentage was 72.4 and 71.64% on 786-0 and ACHN cell lines, respectively ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}).

![Percent inhibition of compound (**5l**) against 22 cell lines from the NCI-60 cell lines that exhibit the percent inhibition range from 50 to 125% (red: \>90%, blue: 80--90%, green: 70--80%, black: \<70%).](ao0c01829_0005){#fig4}

### 2.3.2. Ligand-Based Target Fishing and Kinase Screening {#sec2.3.2}

In pursuit of identifying a possible molecular kinase target(s) for the prepared series of compounds, the ligand-based target fishing (LBTF) approach was adopted ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}), implementing 3D similarity searching between a query compound (**5l**) and a target-annotated compound database, binding database ([www.bindingdb.org](www.bindingdb.org)) (downloaded on June 6th 2018, 1.4 M compounds).^[@ref75]−[@ref77]^ The FastROCS shape comparison software toolkit^[@ref78]^ was used for the 3D similarity searching. The target fishing results are shown in Table T1 in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c01829/suppl_file/ao0c01829_si_001.pdf). Among the targets of the 500 compounds most similar to **5l**, 21 kinases were retrieved. Of the 21 resulting kinases, the following 8 kinases were discarded: (i) adenosine kinase and (ii) leucine-rich repeat serine/threonine-protein kinase 2 (no relation to cancer), (iii) serine/threonine-protein kinase PknB (PknB) (not present in human genome), (iv) serine/threonine-protein kinase PLK1 (PLK1), (v) dual-specificity protein kinase CLK3 (CLK3), and (vi) vascular endothelial growth factor receptor 3 (VEGFR3) (low activity of the resulting compounds, with IC~50~ \> 10 μM), (vii) dual specificity protein kinase CLK4 (CLK4), and (viii) casein kinase I (CK1) (only one inhibitor retrieved from the target fishing). GSK-3 alpha (GSK-3α) and serine/threonine-protein kinase pim-3 (PIM3) were considered; to account for the isoform selectivity of the designed compounds within the kinase family, and vascular endothelial growth factor receptor 2 (VEGFR2) was considered in order to test the antiangiogenic effect of the designed compounds, resulting in 16 kinases: cyclin-dependent kinase 1 (CDK1), cyclin-dependent kinase 2 (CDK2), epidermal growth factor receptor (EGFR), fibroblast growth factor receptor 1 (FGFR1), GSK-3α, GSK-3 beta (GSK-3β), insulin-like growth factor 1 receptor (IGF1R), VEGFR2, mitogen-activated protein kinase 8 (MAPK8), MAP kinase-interacting serine/threonine-protein kinase 1 (MKNK1), serine/threonine-protein kinase pim-1 (PIM1), serine/threonine-protein kinase pim-2 (PIM2), serine/threonine-protein kinase pim-2 (PIM3), phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3C2A), MAP3K7-binding protein 1 (TAK1/TAB1), and hepatocyte growth factor receptor (MET).

![Computational LBTF workflow.](ao0c01829_0006){#fig5}

Compound **5l** was screened on 16 kinases to investigate for the possible mechanism underlying its anticancer activity. The 16 kinases are distributed through the kinase families as follows: (i) the CAMK group (MKNK1 and PIM1/2/3), (ii) the CMGC group (CDK1/2, GSK3α/β and MAPK8), (iii) the TK group (EGFR, FGFR1, IGF1R, VEGFR2 and MET), (iv) lipid kinase (PI3K-C2α), and (v) the STE group (MAP3K7). Compound **5l** was screened over the kinases to determine percent inhibition at 10 μM concentration. GSK-3β was determined to have the highest percent inhibition with 71% ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}). The screening results showed **5l** selectivity toward GSK-3β kinase over the rest of the kinases especially CDK1 and CDK2, which have high sequence similarity with GSK-3β,^[@ref53]^ with 7 and 14 folds, respectively.

![Results of kinase screening of compound **5l** on the 16 kinases represented in kinase percent inhibition at a concentration of 10 μM. The experiments were conducted in duplicates.](ao0c01829_0007){#fig6}

IC~50~ of **5l** on GSK-3β was then measured to be 0.883 ± 0.0294 μM. The **AR-A014418** GSK-3β inhibitor^[@ref79]^ was used as a reference with measured IC~50~ = 0.370 ± 0.0111 μM.

### 2.3.3. Effect of **5l** on Caspase-3 Level {#sec2.3.3}

Caspase-3 (active) level measurement and cell cycle analysis were performed on PC-3 prostate cancer cells, which were chosen because of the reported correlation between GSK-3β inhibition and prostate cancer cells suppressed proliferation in vitro^[@ref45]−[@ref49]^ and suppressed tumor growth in xenograft in vivo.^[@ref50]^ GSK-3β inhibition induces apoptosis in cancer cell lines,^[@ref80]^ so that the active caspase-3 level was evaluated in PC-3 cells in order to confirm the cytotoxic activity of **5l** on PC-3 cells and compared to its levels in control untreated PC-3 cells. As shown in [Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}, caspase-3 was 7.63-fold higher in **5l**-treated PC-3 cells compared to control. These results further confirm the apoptotic potential of **5l**.

![Caspase-3 (active) levels measured in both **5l**-treated and untreated cells. Values are presented as means ± S.D. from three independent experiments performed in triplicates. \**p* \< 0.05 significant from control untreated PC-3 cells using the Student's *t*-test.](ao0c01829_0008){#fig7}

### 2.3.4. Effect of **5l** on Cell Cycle {#sec2.3.4}

Cell cycle analysis showed that **5l** caused cell cycle arrest at the G2-M phase, as shown in [Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}. The number of **5l**-treated cells were 2.1- and 12.9-fold higher in the G2 and pre-G1 phases, compared to control, respectively. In addition, **5l** caused 10.5- and 63.7-fold increase in early and late apoptotic cells, respectively, as compared to control. Moreover, **5l** treatment caused a 2-fold increase in necrotic cells compared to control. These results, together with NCI results, strongly suggest that compound **5l** has an antiproliferative effect on PC-3 cells.

![PC-3 cell cycle analysis results. (a) Histograms representing the cell cycle phases in **5l**-treated cells compared to control untreated cells. (b) Annexin V-FITC and PI-double stained untreated vs **5l**-treated PC-3 cells analyzed with flowcytometry. Percentages of living (bottom left), early apoptotic (bottom right), necrotic (top left), and late apoptotic (top right) cells are shown. (c) Stacked histogram representing cells percentages of each cell cycle phase in **5l**-treated PC-3 cells compared to control.](ao0c01829_0009){#fig8}

2.4. Molecular Modeling {#sec2.4}
-----------------------

### 2.4.1. Molecular Docking {#sec2.4.1}

The molecular docking experiment was conducted in order to predict the binding mode of **5l** inside the GSK-3β ATP binding site. The GSK-3β protein structure co-crystallized with **AR-A014418**, the compound used as a reference in GSK-3β IC~50~ determination (PDB ID: 1Q5K),^[@ref79]^ was used as protein. Docking was carried out using FRED and HYBRID modules of OpenEye software.^[@ref81]−[@ref83]^ Both applications used the same search algorithm and scoring function; however, HYBRID utilizes co-crystallized ligand pose information to improve binding pose prediction, unlike FRED which docks ligands blindly. First, docking validation for both modules was done through the pose retrieval experiment by docking **AR-A014418** in the binding site and measuring root-mean-square deviation (rmsd) between the co-crystallized and docked poses. rmsd was measured to be 8.357 Å and 0.599 Å, for FRED and HYBRID, respectively, which gives HYBRID better credibility in pose prediction over FRED. The docked pose predicted by HYBRID reproduces the same interactions that the co-crystallized pose possesses \[hydrogen bonds with valine 135 (Val135) and proline 136 (Pro136) amino acids of the hinge region\], while the FRED-predicted pose failed to reproduce such interactions showing a great deviation from the co-crystallized pose ([Figure [9](#fig9){ref-type="fig"}](#fig9){ref-type="fig"}).

![Docking validation results. HYBRID-predicted docked pose of **AR-A014418** (blue) is superimposed with the co-crystallized **AR-A014418** (green) with rmsd = 0.599 Å, while the docked pose predicted by FRED (yellow) shows a great deviation with rmsd = 8.357 Å. Hydrogen bonds of co-crystallized **AR-A014418** (green dashed lines) with Val135 and Pro136 are conserved by HYBRID docked pose (cyan dashed lines), while the FRED docked pose shows no hydrogen bonds with the protein amino acids. Valine 135 and proline 136 amino acids of the hinge region are depicted in coral, while the protein ribbon in gray colors.](ao0c01829_0010){#fig9}

Docking of **5l** with both FRED and HYBRID was used to predict the binding mode of **5l** inside the ATP binding pocket of GSK-3β. The binding pose predicted by HYBRID, referred to as **5l**\_HYBRID throughout the text, was similar to the reported pose of GSK-3 inhibitors with pyrazolpyridine and pyrazolopyridazine scaffolds similar to triazolothiadiazines^[@ref52],[@ref53]^ ([Figure [10](#fig10){ref-type="fig"}](#fig10){ref-type="fig"}). They are reported to have two hydrogen bonds with Val135, where N2 of the pyrazole acts a hydrogen bond acceptor and NH at position 3 acts as a hydrogen bond donor and one hydrogen bond with aspartate (Asp133), where NH at position 1 of the pyrazole acts a hydrogen bond donor. Lacking the hydrogen bond donor NH at position 1 of triazolothiadiazine makes it lose the hydrogen bond with Asp133, while having hydrogen bond acceptor N2 of triazole and hydrogen bond donor NH at position 3 makes it keep the two hydrogen bonds with Val135. In addition, the 4-cholorophenyl is placed in the back pocket of the ATP binding site and the 4-CF~3~ phenyl hydrazone is positioned toward the solvent accessible region, similar to the reported pyrazolopyridazine GSK-3 inhibitor ([Figure [10](#fig10){ref-type="fig"}](#fig10){ref-type="fig"}). On the other hand, the binding pose predicted by FRED, referred to as **5l**\_FRED throughout the text, is flipped with regard to the pose reported by pyrazolpyridines and pyrazolopyridazines GSK-3 inhibitors ([Figure [10](#fig10){ref-type="fig"}](#fig10){ref-type="fig"}). The 4-chlorophenyl is positioned toward the solvent accessible region, and the 4-CF~3~ phenyl hydrazone is placed in the back pocket of the ATP binding site. It is also predicted to make a hydrogen bond with Val135 through the hydrogen bond donor NH at position 3.

![Left: Reported binding mode of a pyrazolopyridazine GSK-3 inhibitor (gray) with three hydrogen bonds with Asp133 and Val135 (green dashed lines). Right: Binding mode of **5l** predicted by FRED (**5l**\_FRED, orange), showing one hydrogen bond formed with Val135 (orange dashed line), and HYBRID (**5l**\_HYBRID, green), showing two hydrogen bonds formed with Val135 (green dashed lines).](ao0c01829_0011){#fig10}

### 2.4.2. Molecular Dynamics {#sec2.4.2}

Molecular dynamics (MD) simulations were conducted to test the stability of **5l** binding modes predicted by both FRED (**5l**\_FRED) and HYBRID (**5l**\_HYBRID) docking. **AR-A014418** was also subjected for MD simulations to account for its binding mode and protein dynamics as a reference, resulting in a total of three MD runs. MD was carried out for 20 ns each, at *NPT* ensemble (constant number of particles, pressure, and temperature), for minimization and equilibration purposes.

The rmsd, a measure of time-dependent structure stability, is measured for protein backbone atoms (C~α~, C, and N) for the three MD runs ([Figure [11](#fig11){ref-type="fig"}](#fig11){ref-type="fig"}). The rmsd reached stability after 1 ns with no prominent fluctuation throughout the three MD runs. The average rmsd was 1.60 ± 0.21, 1.69 ± 0.26, and 1.53 ± 0.22 Å (mean ± SD) for **AR-A014418**, **5l**\_HYBRID, and **5l**\_FRED proteins, respectively. These results give an indication of proteins stability during the three runs. Protein residue conformational changes and stability are measured by per residue root-mean-square fluctuation (RMSF) ([Figure [11](#fig11){ref-type="fig"}](#fig11){ref-type="fig"}). All amino acid residues of the binding site have RMSF \< 1 Å, which indicates a relatively stable binding with **AR-A014418**, **5l**\_HYBRID and **5l**\_FRED and minimal local conformational changes in the binding site. Protein compactness and equilibrium conformation were assessed by measuring the protein radius of gyration (*R*~g~) throughout the simulation time ([Figure [11](#fig11){ref-type="fig"}](#fig11){ref-type="fig"}). *R*~g~ values show consistency within the three experiments, which is an indication of protein conformational stability throughout the simulation time. As shown in [Figure [11](#fig11){ref-type="fig"}](#fig11){ref-type="fig"}, *R*~g~ values are 44.7 ± 0.12, 44.7 ± 0.12, and 44.7 ± 0.12 Å (mean ± SD) for **AR-A014418**, **5l**\_HYBRID, and **5l**\_FRED proteins, respectively. The time stability of *R*~g~ confirms our knowledge that major conformational changes need micro-to-milli second simulation time period to emerge, on the contrary to the nanosecond time scale, in which major protein conformational changes rarely occur.

![Top: Protein rmsd of the three MD runs showing stability after 1 ns and minimal fluctuation throughout the simulation time. Middle: Per residue RMSF of the three MD runs showing RMSF \< 1 Å for the binding site residues (colored rectangles) with low RMSF in the hinge region residues (red rectangle). Bottom: Protein radius of gyration (*R*~g~) of the three MD runs showing compactness of the protein throughout the simulation time with no major conformational changes. **AR-A014418**, **5l**\_HYBRID, and **5l**\_FRED proteins are depicted in green, blue, and yellow colors, respectively.](ao0c01829_0012){#fig11}

![rmsd of the ligand during the three MD runs: **AR-A014418** (green), **5l**\_HYBRID docked pose (blue), and **5l**\_FRED docked pose (yellow). The **5l**\_FRED docked pose shows the highest deviation which indicates the instability of this binding pose.](ao0c01829_0013){#fig12}

Ligand rmsd analysis throughout the time of simulation showed **AR-A014418** to have the least deviation from the co-crystallized pose, with an rmsd of 1.46 ± 0.34 Å (mean ± SD). Comparing **5l**\_HYBRID and **5l**\_FRED ligands rmsd analysis revealed a greater deviation of **5l**\_FRED than that of **5l**\_HYBRID with an average rmsd of 2.08 ± 0.46 and 2.71 ± 0.44 Å (mean ± SD) for **5l**\_HYBRID and **5l**\_FRED, respectively ([Figure [12](#fig12){ref-type="fig"}](#fig12){ref-type="fig"}). This indicates that **5l**\_FRED abandoned its initial pose, depicted in [Figure [10](#fig10){ref-type="fig"}](#fig10){ref-type="fig"}, to another distant binding mode. However, **5l**\_HYBRID had more stable binding mode indicated by its lower rmsd and bidentate-hydrogen-bond anchorage with the Val135 hinge region amino acid ([Figure [12](#fig12){ref-type="fig"}](#fig12){ref-type="fig"}).

Hydrogen bonding analysis between the ligands and their proteins was carried out in order to investigate the hydrogen bonding contribution to the overall binding interactions. **AR-A014418**, **5l**\_HYBRID, and **5l**\_FRED had 0.67 ± 0.57, 0.64 ± 0.56, and 0.59 ± 0.52 Å (mean ± SD) hydrogen bonds through the 20 ns simulation time. The lower average number of **5l**\_FRED hydrogen bonds with its protein indicates its weaker binding compared to the number of hydrogen bonds of **AR-A014418** and **5l**\_HYBRID with their proteins that showed comparable binding stability ([Figure [13](#fig13){ref-type="fig"}](#fig13){ref-type="fig"}). The main hydrogen bonding interaction is shown to be with the carbonyl and amine moieties of the Val135 residue. This is depicted in [Figure [13](#fig13){ref-type="fig"}](#fig13){ref-type="fig"} in which hydrogen bonds with the ligands and their proteins are compared with their hydrogen bonds with the Val135 amino acid. Both **AR-A014418** and **5l**\_HYBRID maintain their hydrogen bonding interactions with Val135. On the other hand, **5l**\_FRED lost its hydrogen bonding interactions with Val135 in the first few picoseconds of the simulation. The one hydrogen bond kept by **5l**\_FRED is attributed to the Pro136 hydrogen bond acceptor carbonyl moiety.

![Number of hydrogen bonds formed during the simulation time between the ligands and the protein (left), and the ligands and Valine 135 (right).](ao0c01829_0014){#fig13}

Finally, comparing rmsd of docked poses of **5l**\_HYBRID and **5l**\_FRED makes the HYBRID-predicted docking pose more acceptable. The lower rmsd of **5l**\_HYBRID and its higher number of hydrogen bonds throughout the MD simulation assures **5l**\_HYBRID pose stability. These results together suggest **5l**\_HYBRID to be the binding mode adopted by **5l** inside the GSK-3β protein.

3. Conclusions {#sec3}
==============

**5l** has been discovered to be a novel GSK-3β inhibitor with antiproliferative activity on the PC-3 prostate cancer cell line through NCI-60 cancer cell line screening and LBTF. This study has demonstrated the apoptotic effect of **5l** on PC-3 cells as shown by its ability to increase active caspase-3 levels and arrest cell cycle at G2-M phase. A combination of molecular docking and dynamics simulations was used in predicting the binding mode of **5l**, which adopted that of reported similar pyrazolopyridazine GSK-3 inhibitors. **5l** can be used as a scaffold for further development of GSK-3β inhibitors.

4. Experimental Section {#sec4}
=======================

4.1. Chemistry {#sec4.1}
--------------

### 4.1.1. General {#sec4.1.1}

Starting materials and reagents were purchased from Sigma-Aldrich (USA) or Alfa Aesar Organics and used without further purification. Solvents were purchased from Fisher Scientific or Sigma-Aldrich and used without further purification. Reactions were monitored by analytical TLC, performed on silica gel 60 F254 packed on aluminum sheets, purchased from Merck, with visualization under UV light (254 nm). Melting points were recorded on Stuart Scientific apparatus and were uncorrected. ^1^HNMR spectra were recorded in δ scale given in ppm on a Bruker 400 MHz spectrophotometer and referred to trimethylsilyl at Cairo University. ^13^CNMR spectra were recorded in δ scale given in ppm on a Bruker 101 MHz spectrophotometer at Cairo University. FT-IR spectra were recorded on a Thermo Scientific Nicolet iS10 spectrometer at Ain Shams University. Electron ionization (EI)--mass spectroscopy (MS) spectra were recorded on a Thermo Scientific ISOLT mass spectrometer at the Regional Center for Mycology and Biotechnology, Al-Azhar University. Elemental analyses were performed on a Thermo Scientific Flash 2000 elemental analyzer at the Regional Center for Mycology and Biotechnology, Al-Azhar University.

### 4.1.2. Synthesis {#sec4.1.2}

#### 4.1.2.1. General Procedure for the Preparation of **3a**,**b** {#sec4.1.2.1}

A solution of 4-amino-5-hydrazinyl-4*H*-1,2,4-triazole-3-thiol (purpald) (**1**, 1 equiv, 30.1 mmol, 4.4 g) in 1 M HCl (60 mL) was heated till complete dissolution. Then, the respective 2-bromo-4′-substituted acetophen-1-one (**2**, 0.9 equiv, 27.09 mmol) dissolved in hot absolute methanol (60 mL) was added to 4-amino-5-hydrazineyl-4*H*-1,2,4-triazole-3-thiol (purpald) HCl solution dropwise over 15 min. The reaction mixture was heated under reflux for 45 min. The reaction mixture was then diluted with 20 mL water portionwise while hot and then left to crystallize at room temperature for 3 h and in the freezer overnight. The reaction mixture was then filtered, washed with minimal amount of water (10 mL), and dried to afford the titled compounds **3a--b**. The compound is purified by crystallization form aqueous ethanol to yield pure crystals.

#### 4.1.2.2. 2-(6-Phenyl-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydrazin-1-ium Chloride (**3a**) {#sec4.1.2.2}

The titled compound was separated as yellowish white crystals (6.13 g, 80%); mp 205--206 °C; ^1^H-NMR (400 MHz, DMSO-*d*~6~): δ 4.34 (s, 2H), 7.52--7.62 (m, 3H), 8.00 (d, *J* = 7.3 Hz, 2H), 10.18 (br s, 1H, NH, D~2~O exchangeable). ^13^C-NMR (100 MHz, DMSO-*d*~6~): δ 23.2, 128.1, 129.4, 132.7, 133.3, 139.9, 151.3, 156.1. FTIR (KBr, cm^--1^) *ṽ*: 3727, 3482, 3380, 3310, 3261, 3205, 3004, 2910, 2790, 2742, 1734, 1630, 1546, 1448, 1415, 1287, 1228, 1194, 1163, 1062, 1049, 1025, 1007, 935, 910, 852, 828, 772, 741, 693, 675, 627, 603, 562, 499. EI-MS: (*M*~wt~: 282.75): *m*/*z* (% rel. int.), 282.34 \[M^+^, (16.15%)\], 75.11 (100%); Anal. Calcd for C~10~H~11~ClN~6~S: C, 42.48; H, 3.92; N, 29.72. Found: C, 42.71; H, 3.85; N, 29.89.

#### 4.1.2.3. 2-(6-(4-Chlorophenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydrazin-1-ium Chloride (**3b**) {#sec4.1.2.3}

The titled compound was separated as yellowish white crystals (6.78 g, 79%); mp 184--185 °C; ^1^H-NMR (400 MHz, DMSO-*d*~6~): δ 4.48 (s, 2H), 7.67 (d, *J* = 8.7 Hz, 2H), 8.13 (d, *J* = 8.7 Hz, 2H), 9.95 (br s, 1H, NH). FTIR (KBr, cm^--1^) *ṽ*: 3726, 3410, 3339, 3250, 3130, 3080, 2987, 2921, 2671, 1711, 1590, 1543, 1494, 1415, 1396, 1332, 1278, 1222, 1194, 1089, 1043, 1010, 933, 906, 844, 752, 709, 640, 571, 503, 471, 457, 419. EI-MS: (*M*~wt~: 317.19): *m*/*z* (% rel. int.), 319.61 \[M^+^ + 2, (27.33%)\], 317.14 \[M^+^, (34.92%)\], 253.44 (100%); Anal. Calcd for C~10~H~10~Cl~2~N~6~S: C, 37.87; H, 3.18; N, 26.50. Found: C, 38.11; H, 3.27; N, 26.78.

#### 4.1.2.4. General Procedure for the Preparation of **5a--t** {#sec4.1.2.4}

A solution of the 2-(6-(4-substituted)phenyl-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazin-3-yl)hydrazin-1-ium chloride (**3a**,**b**) (1 equiv, 3.5 mmol) in 50% ethanol (30 mL) was stirred under reflux until dissolution. Then, the freshly prepared solution of aldehyde (**4**, 0.9 equiv, 3.15 mmol) in ethanol (5 mL) was added to the reaction mixture. The reaction mixture was maintained under reflux for 2 h and quenched with 5 mL saturated Na~2~CO~3~ solution. The crude product was isolated by hot filtration, followed by crystallization from 50% aqueous dimethylformamide (DMF). The product was then dried under vacuum in a vacuum oven overnight.

#### 4.1.2.5. (*E*)-3-(2-Benzylidenehydrazinyl)-6-phenyl-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazine (**5a**) {#sec4.1.2.5}

The titled compound was crystallized from aqueous DMF as yellow crystals (0.92 g, 87.3%); mp 220--223 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 10.92 (s, 1H, NH, D~2~O exchangeable), 8.47 (s, 1H, CH), 8.18--8.07 (m, 2H, Ar H), 7.72--7.64 (m, 2H, Ar H), 7.65--7.54 (m, 3H, Ar H), 7.48--7.34 (m, 3H, Ar H), 4.41 (s, 2H, CH~2~). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 154.38, 151.39, 144.60, 137.56, 135.18, 133.90, 132.21, 129.75, 129.37, 129.24, 128.01, 126.88, 40.33. FTIR (KBr, cm^--1^) *ṽ*: 3140, 3060, 3010, 2966, 1732, 1716, 1610, 1590, 1526, 1473, 1445, 1392, 1328, 1307, 1392, 1328, 1307, 1293, 1227, 1174, 1113, 1057, 1013, 945, 894, 834, 760, 688, 615, 599, 507, 471, 458. EI-MS: (*M*~wt~: 334.10): *m*/*z* (% rel. int.), 334.00, \[M^+^, (20.89%)\], 254.75 (100%); Anal. Calcd for C~17~H~14~N~6~S: C, 61.06; H, 4.22; N, 25.13; S, 9.59. Found: C, 60.87; H, 4.38; N, 25.39; S, 9.67.

#### 4.1.2.6. (*E*)-6-Phenyl-3-(2-(4-(trifluoromethyl)benzylidene)hydrazinyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazine (**5b**) {#sec4.1.2.6}

The titled compound was crystallized from aqueous DMF as yellow crystals (1.13 g, 89.2%); mp 207--215 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 11.24 (s, 1H, NH, D~2~O exchangeable), 8.55 (s, 1H, CH), 8.12 (s, *J* = 8 Hz, 2H, Ar H), 7.89 (d, *J* = 7.9 Hz, 2H, Ar H), 7.78 (d, *J* = 8.1 Hz, 2H, Ar H), 7.65--7.53 (m, 3H, Ar H), 4.42 (s, 2H, CH~2~). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 154.48, 151.09, 142.53, 139.33, 137.74, 133.96, 132.17, 129.33, 128.04, 127.30, 126.09, 126.05, 123.30, 40.10. FTIR (KBr, cm^--1^) *ṽ*: 3622, 3529, 3124, 3020, 2912, 2858, 2827, 2638, 1620, 1597, 1535, 1481, 1446, 1396, 1327, 1230, 1103, 1068, 1014, 987, 925, 898, 840, 821, 759, 732, 686, 594. EI-MS: (*M*~wt~: 402.08): *m*/*z* (% rel. int.), 402.24 \[M^+^, (17.75%)\], 57.47 (100%); Anal. Calcd for C~18~H~13~F~3~N~6~S: C, 53.73; H, 3.26; F, 14.16; N, 20.89; S, 7.97. Found: C, 53.91; H, 3.48; N, 21.23; S, 8.19.

#### 4.1.2.7. (*E*)-3-(2-(3-Methoxybenzylidene)hydrazinyl)-6-phenyl-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazine (**5c**) {#sec4.1.2.7}

The titled compound was crystallized from aqueous DMF as off-white crystals (1 g, 87.1%); mp 212--216 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 10.97 (s, 1H, NH, D~2~O exchangeable), 8.43 (s, 1H, CH), 8.12 (d, *J* = 7.3 Hz, 2H, Ar H), 7.65--7.53 (m, 3H, Ar H), 7.35 (t, *J* = 7.9 Hz, 1H, Ar H), 7.29--7.20 (m, 2H, Ar H), 6.96 (dd, *J* = 7.9, 2.9 Hz, 1H, Ar H), 4.41 (s, 2H, CH~2~), 3.79 (s, 3H, CH~3~). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 159.99, 154.33, 151.31, 144.28, 137.51, 136.77, 134.00, 132.15, 130.32, 129.35, 128.03, 119.84, 115.81, 110.97, 55.56, 40.11. FTIR (KBr, cm^--1^) *ṽ*: 3167, 3001, 2970, 2920, 2835, 1610, 1581, 1535, 1269, 1114, 686. EI-MS: (*M*~wt~: 364.11): *m*/*z* (% rel. int.), 364.67 \[M^+^, (11.56%)\], 51.49 (100%); Anal. Calcd for C~18~H~16~N~6~OS: C, 59.33; H, 4.43; N, 23.06; O, 4.39; S, 8.80. Found: C, 59.60; H, 4.56; N, 22.94; S, 8.87.

#### 4.1.2.8. (*E*)-3-(2-(4-Hydroxy-3-methoxybenzylidene)hydrazinyl)-6-phenyl-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazine (**5d**) {#sec4.1.2.8}

The titled compound was crystallized from aqueous DMF as yellow crystals (1.07 g, 89.2%); mp 210--213 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 10.69 (s, 1H, NH, D~2~O exchangeable), 9.42 (s, 1H, OH, D~2~O exchangeable), 8.35 (s, 1H, CH), 8.16--8.09 (m, 2H, Ar H), 7.71--7.52 (m, 3H, Ar H), 7.27 (d, *J* = 1.9 Hz, 1H, Ar H), 7.03 (dd, *J* = 8.2, 1.9 Hz, 1H, Ar H), 6.83 (d, *J* = 8.1 Hz, 1H, Ar H), 4.40 (s, 2H, CH~2~), 3.80 (s, 3H, OCH~3~). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 154.18, 151.61, 148.62, 148.48, 145.25, 137.29, 133.97, 132.14, 129.35, 127.98, 126.76, 121.70, 115.81, 108.95, 55.95, 40.38. FTIR (KBr, cm^--1^) *ṽ*: 3619, 3566, 3136, 3005, 2966, 2935, 1636, 1609, 1513, 1445, 1463, 1431, 1402, 1349, 1340, 1328, 1291, 1272, 1254, 1196, 1167, 1122, 1099, 1062, 1032, 860, 822, 759, 690, 623, 605, 593. EI-MS: (*M*~wt~: 380.1): *m*/*z* (% rel. int.), 380.73 \[M^+^, (28.87%)\], 364.40 (100%); Anal. Calcd for C~18~H~16~N~6~O~2~S: C, 56.83; H, 4.24; N, 22.09; O, 8.41; S, 8.43. Found: C, 57.06; H, 4.38; N, 22.31; S, 8.29.

#### 4.1.2.9. (*E*)-6-Phenyl-3-(2-(4-(dimethylamino)benzylidene)hydrazinyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazine (**5e**) {#sec4.1.2.9}

The titled compound was crystallized from aqueous DMF as yellowish brown crystals (1.03 g, 86.6%); mp 216--220 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 10.55 (s, 1H, NH, D~2~O exchangeable), 8.33 (s, 1H, CH), 8.21--8.06 (m, 2H, Ar H), 7.69--7.54 (m, 3H, Ar H), 7.50 (d, *J* = 8.5 Hz, 2H, Ar H), 6.75 (d, *J* = 8.8 Hz, 2H, Ar H), 4.38 (s, 2H, CH~2~), 2.96 (s, 6H, 2CH~3~). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 153.85, 151.76, 151.45, 145.74, 136.96, 134.06, 132.04, 129.31, 128.16, 127.98, 122.82, 112.35, 40.53. FTIR (KBr, cm^--1^) *ṽ*: 3178, 3124, 3093, 3066, 2993, 2889, 2858, 2804, 1597, 1581, 1527, 1512, 1473, 1446, 1365, 1303, 1234, 1180, 1095, 1056, 945, 802, 748, 694, 524. EI-MS: (*M*~wt~: 377.14): *m*/*z* (% rel. int.), 377.13 \[M^+^, (27.01%)\], 160.53 (100%); Anal. Calcd for C~19~H~19~N~7~S: C, 60.46; H, 5.07; N, 25.98; S, 8.49. Found: C, 60.75; H, 5.11; N, 26.23; S, 8.61.

#### 4.1.2.10. (*E*)-3-(2-(\[1,1′-Biphenyl\]-4-ylmethylene)hydrazinyl)-6-phenyl-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazine (**5f**) {#sec4.1.2.10}

The titled compound was crystallized from aqueous DMF as dark yellow crystals (1.13 g, 87.3%); mp 218--220 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 10.99 (s, 1H, NH, D~2~O exchangeable), 8.52 (s, 1H, CH), 8.15 (d, *J* = 8.0, 2H, Ar H), 7.81--7.70 (m, 6H, Ar H), 7.65--7.54 (m, 3H, Ar H), 7.49 (t, *J* = 7.6 Hz, 2H, Ar H), 7.43--7.36 (m, 1H, Ar H), 4.42 (s, 2H, CH~2~). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 154.26, 151.34, 143.96, 141.12, 139.93, 137.43, 134.51, 134.05, 132.13, 129.46, 129.34, 128.17, 128.05, 127.43, 127.05, 40.62, 40.46. FTIR (KBr, cm^--1^) *ṽ*: 3566, 3447, 3156, 3053, 3206, 2993, 2900, 1610, 1590, 1556, 1484, 1353, 1291, 1098, 1075, 902, 840, 723, 618. EI-MS: (*M*~wt~: 410.13): *m*/*z* (% rel. int.), 410.13 \[M^+^, (31.43%)\], 248.40 (100%); Anal. Calcd for C~23~H~18~N~6~S: C, 67.30; H, 4.42; N, 20.47; S, 7.81. Found: C, 67.53; H, 4.59; N, 20.39; S, 7.98.

#### 4.1.2.11. (*E*)-3-(2-(4-(Benzyloxy)benzylidene)hydrazinyl)-6-phenyl-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazine (**5g**) {#sec4.1.2.11}

The titled compound was crystallized from aqueous DMF as yellow crystals (1.2 g, 86.4%); mp 213--215 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 10.75 (s, 1H, NH, D~2~O exchangeable), 8.41 (s, 1H, CH), 8.13 (d, *J* = 7.0 Hz, 2H, Ar H), 7.73--7.51 (m, 5H, Ar H), 7.48 (d, *J* = 7.0 Hz, 2H, Ar H), 7.45--7.38 (m, 2H, Ar H), 7.38--7.31 (m, 1H, Ar H), 7.09 (d, *J* = 8.4 Hz, 2H, Ar H), 5.16 (s, 2H, OCH~2~), 4.40 (s, 2H, CH~2~). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 159.70, 144.55, 137.32, 137.25, 133.97, 132.13, 129.35, 128.93, 128.43, 128.38, 128.18, 128.11, 127.98, 115.57, 69.78, 40.40. FTIR (KBr, cm^--1^) *ṽ*: 3446, 3160, 3060, 3010, 2914, 2868, 1605, 1508, 1474, 1380, 1247, 1170, 1007, 954, 921, 898, 833, 764, 751, 696, 622, 601, 531, 517, 472, 435. EI-MS: (*M*~wt~: 440.14): *m*/*z* (% rel. int.), 440.87 \[M^+^, (42.51%)\], 399.26 (100%); Anal. Calcd for C~24~H~20~N~6~OS: C, 65.44; H, 4.58; N, 19.08; O, 3.63; S, 7.28. Found: C, 65.31; H, 4.75; N, 19.36; S, 7.09.

#### 4.1.2.12. (*E*)-3-(2-(Furan-2-ylmethylene)hydrazinyl)-6-phenyl-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazine (**5h**) {#sec4.1.2.12}

The titled compound was crystallized from aqueous DMF as buff crystals (0.85 g, 83.1%); mp 190--196 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 10.90 (s, 1H, NH, D~2~O exchangeable), 8.44 (s, 1H, CH), 8.19--8.08 (m, 2H, Ar H), 7.80 (d, *J* = 1.9 Hz, 1H, furan H), 7.65--7.52 (m, 3H, Ar H), 6.80 (d, *J* = 3.4 Hz, 1H, furan H), 6.62 (dd, *J* = 3.4, 1.8 Hz, 1H, furan H), 4.40 (s, 2H, CH~2~). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 154.36, 151.16, 150.37, 144.72, 137.40, 134.77, 133.97, 132.16, 129.34, 128.06, 112.48, 111.90, 40.11. FTIR (KBr, cm^--1^) *ṽ*: 3525, 3421, 3143, 3097, 3059, 3012, 2958, 2900, 2804, 1589, 1465, 1327, 1111, 1060, 1014, 933, 732, 686, 590. EI-MS: (*M*~wt~: 324.07): *m*/*z* (% rel. int.), 324.60 \[M^+^, (22.81%)\], 256.75 (100%); Anal. Calcd for C~15~H~12~N~6~OS: C, 55.54; H, 3.73; N, 25.91; O, 4.93; S, 9.88. Found: C, 55.79; H, 3.81; N, 26.14; S, 9.97.

#### 4.1.2.13. (*E*)-6-Phenyl-3-(2-(thiophen-3-ylmethylene)hydrazinyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazine (**5i**) {#sec4.1.2.13}

The titled compound was crystallized from aqueous DMF as buff crystals (0.94 g, 87.6%); mp 210--212 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 10.79 (s, 1H, NH, D~2~O exchangeable), 8.55 (s, 1H, CH), 8.12 (d, *J* = 7.2 Hz, 2H, Ar H), 7.80 (d, *J* = 3.4 Hz, 1H, thiophene H), 7.65--7.53 (m, 4H, Ar and thiophene H), 7.46 (d, *J* = 5.1 Hz, 1H, thiophene H), 4.40 (s, 2H, CH~2~). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 154.19, 151.33, 140.50, 138.46, 137.26, 134.05, 132.11, 129.32, 128.05, 127.86, 126.51, 124.91, 40.63. FTIR (KBr, cm^--1^) *ṽ*: 3503, 3148, 3057, 2950, 2905, 1680, 1590, 1534, 1473, 1384, 1332, 1309, 1288, 1224, 1242, 1164, 1108, 1075, 871, 821, 780, 755, 686, 643, 628, 600, 558, 472. EI-MS: (*M*~wt~: 340.05): *m*/*z* (% rel. int.), 340.72 \[M^+^, (36.74%)\], 103.33 (100%); Anal. Calcd for C~15~H~12~N~6~S~2~: C, 52.92; H, 3.55; N, 24.69; S, 18.84. Found: C, 53.17; H, 3.71; N, 24.95; S, 18.97.

#### 4.1.2.14. (*E*)-3-(2-((1*H*-Indol-3-yl)methylene)hydrazinyl)-6-phenyl-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazine (**5j**) {#sec4.1.2.14}

The titled compound was crystallized from aqueous DMF as yellow crystals (1.06 g, 89%); mp 206--212 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 11.45 (s, 1H, NH, indole NH′, D~2~O exchangeable), 10.45 (s, 1H, NH, D~2~O exchangeable), 8.58 (s, 1H, CH), 8.28 (d, *J* = 7.9 Hz, 1H, indole H), 8.20--8.10 (m, 2H, Ar H), 7.72 (d, *J* = 2.7 Hz, 1H, indole H), 7.58 (qd, *J* = 8.7, 7.8, 3.6 Hz, 3H, Ar H), 7.42 (dt, *J* = 8.0, 1.0 Hz, 1H, indole H), 7.18 (ddd, *J* = 8.2, 7.0, 1.3 Hz, 1H, indole H), 7.04 (ddd, *J* = 8.0, 7.1, 1.1 Hz, 1H, indole H), 4.40 (s, 2H, CH~2~). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 162.86, 153.94, 152.06, 142.23, 137.40, 136.94, 134.14, 132.03, 129.33, 129.11, 128.01, 124.76, 122.91, 122.54, 120.53, 112.44, 112.11, 40.50, 39.88, 39.67, 39.46, 39.25. FTIR (KBr, cm^--1^) *ṽ*: 3170, 3151, 3109, 3055, 2927, 2881, 2738, 3692, 2611, 2569, 2499, 2314, 1662, 1597, 1581, 1469, 1446, 1384, 1099, 752, 666. EI-MS: (*M*~wt~: 373.11): *m*/*z* (% rel. int.), 373.86 \[M^+^, (17.93%)\], 160.29 (100%); Anal. Calcd for C~19~H~15~N~7~S: C, 61.11; H, 4.05; N, 26.26; S, 8.59. Found: C, C, 61.38; H, 4.16; N, 26.44; S, 8.70.

#### 4.1.2.15. (*E*)-3-(2-Benzylidenehydrazinyl)-6-(4-chlorophenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazine (**5k**) {#sec4.1.2.15}

The titled compound was crystallized from aqueous DMF as yellow crystals (1.06 g, 91.2%); mp 216--221 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 10.97 (s, 1H, NH, D~2~O exchangeable), 8.46 (s, 1H, CH), 8.15 (d, *J* = 8.2 Hz, 2H, Ar H), 7.76--7.57 (m, 4H, Ar H), 7.53--7.31 (m, 3H, Ar H), 4.41 (s, 2H, CH~2~). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 153.13, 151.47, 144.77, 137.32, 136.99, 135.28, 132.79, 129.79, 129.69, 129.41, 129.21, 126.89, 40.25. FTIR (KBr, cm^--1^) *ṽ*: 3432, 3144, 3053, 2974, 2917, 1619, 1590, 1486, 1445, 1409, 1325, 1089, 1071, 1008, 986, 885, 808, 756, 699, 649, 564, 529, 517, 474. EI-MS: (*M*~wt~: 368.06): *m*/*z* (% rel. int.), 368.54 \[M^+^, (19.15%)\], 61.98 (100%); Anal. Calcd for C~17~H~13~ClN~6~S: C, 55.36; H, 3.55; Cl, 9.61; N, 22.79; S, 8.69. Found: C, 55.49; H, 3.79; N, 22.63; S, 8.75.

#### 4.1.2.16. (*E*)-6-(4-Chlorophenyl)-3-(2-(4-(trifluoromethyl)benzylidene)hydrazineyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazine (**5l**) {#sec4.1.2.16}

The titled compound was crystallized from aqueous DMF as yellow crystals (1.23 g, 89.3%); mp 226--230 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 11.24 (s, 1H, NH, D~2~O exchangeable), 8.54 (s, 1H, CH), 8.15 (d, *J* = 8.4 Hz, 2H, Ar H), 7.90 (d, *J* = 8.1 Hz, 2H, Ar H), 7.79 (d, *J* = 8.2 Hz, 2H, Ar H), 7.66 (d, *J* = 8.6 Hz, 2H, Ar H), 4.41 (s, 2H, CH~2~). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 153.28, 151.30, 143.15, 139.27, 137.63, 137.04, 132.68, 129.75, 129.47, 129.38, 127.34, 125.99, 123.26, 40.13. FTIR (KBr, cm^--1^) *ṽ*: 3622, 3091, 3027, 2906, 1751, 1602, 1591, 1508, 1479, 1326, 1152, 1092, 1015, 850, 806, 771, 595, 458. EI-MS: (*M*~wt~: 436.04): *m*/*z* (% rel. int.), 436.40 \[M^+^, (27.86%)\], 181.02 (100%); Anal. Calcd for C~18~H~12~ClF~3~N~6~S: C, 49.49; H, 2.77; Cl, 8.12; F, 13.05; N, 19.24; S, 7.34. Found: C, 49.36; H, 2.96; N, 19.08; S, 7.38.

#### 4.1.2.17. (*E*)-6-(4-Chlorophenyl)-3-(2-(3-methoxybenzylidene)hydrazinyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazine (**5m**) {#sec4.1.2.17}

The titled compound was crystallized from aqueous DMF as yellow crystals (1.15 g, 91.5%); mp 212--216 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 10.99 (s, 1H, NH, D~2~O exchangeable), 8.45 (s, 1H, CH), 8.15 (d, *J* = 8.2 Hz, 2H, Ar H), 7.66 (d, *J* = 8.7 Hz, 2H, Ar H), 7.35 (t, *J* = 7.9 Hz, 1H, Ar H), 7.24 (d, *J* = 7.7 Hz, 2H, Ar H), 7.01--6.92 (m, 1H, Ar H), 4.40 (s, 2H, CH~2~), 3.79 (s, 3H, CH~3~). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 159.96, 153.16, 151.44, 144.77, 137.40, 137.01, 136.73, 132.78, 130.32, 129.77, 129.41, 119.95, 115.87, 110.99, 55.56, 40.17. FTIR (KBr, cm^--1^) *ṽ*: 3626, 3161, 3074, 2998, 2970, 2920, 2876, 2831, 1590, 1556, 1473, 1451, 1353, 1281, 1198, 1092, 1079, 1006, 919, 840, 807, 792, 699, 584, 473. EI-MS: (*M*~wt~: 398.07): *m*/*z* (% rel. int.), 398.47 \[M^+^, (29.65%)\], 235.56 (100%); Anal. Calcd for C~18~H~15~ClN~6~OS: C, 54.20; H, 3.79; Cl, 8.89; N, 21.07; O, 4.01; S, 8.04. Found: C, 54.37; H, 4.02; N, 21.30; S, 8.17.

#### 4.1.2.18. (*E*)-6-(4-Chlorophenyl)-3-(2-(4-hydroxy-3-methoxybenzylidene)hydrazinyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazine (**5n**) {#sec4.1.2.18}

The titled compound was crystallized from aqueous DMF as yellow crystals (1.1 g, 84.2%); mp 218--220 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 10.72 (s, 1H, NH, D~2~O exchangeable), 9.43 (s, 1H, OH, D~2~O exchangeable), 8.36 (s, 1H, CH), 8.15 (d, *J* = 8.7 Hz, 2H, Ar H), 7.65 (d, *J* = 8.6 Hz, 2H, Ar H), 7.27 (d, *J* = 1.9 Hz, 1H, Ar H), 7.03 (dd, *J* = 8.2, 1.9 Hz, 1H, Ar H), 6.83 (d, *J* = 8.1 Hz, 1H, Ar H), 4.39 (s, 2H, CH~2~), 3.80 (s, 3H, OCH~3~). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 152.97, 151.48, 148.68, 148.47, 145.21, 136.96, 136.95, 132.90, 129.82, 129.40, 126.79, 121.56, 115.89, 108.97, 55.93, 40.41. FTIR (KBr, cm^--1^) *ṽ*: 3404, 3180, 3038, 2996, 2922, 2736, 2599, 1640, 1617, 1555, 1522, 1480, 1428, 1408, 1341, 1317, 1288, 1260, 1200, 1107, 1064, 1035, 849, 781, 746, 655, 575, 468. EI-MS: (*M*~wt~: 414.06): *m*/*z* (% rel. int.), 414.03 \[M^+^, (49.90%)\], 164.56 (100%); Anal. Calcd for C~18~H~15~ClN~6~O~2~S: C, 52.11; H, 3.64; Cl, 8.54; N, 20.26; O, 7.71; S, 7.73. Found: C, 51.97; H, 3.88; N, 20.59; S, 7.82.

#### 4.1.2.19. (*E*)-6-(4-Chlorophenyl)-3-(2-(4-(dimethylamino)benzylidene)hydrazinyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazine (**5o**) {#sec4.1.2.19}

The titled compound was crystallized from aqueous DMF as yellow crystals (1.13 g, 87.2%); mp 209--212 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 10.54 (s, 1H, NH, D~2~O exchangeable), 8.32 (s, 1H, CH), 8.16 (d, *J* = 8.6 Hz, 2H, Ar H), 7.66 (d, *J* = 8.6 Hz, 2H, Ar H), 7.50 (d, *J* = 8.7 Hz, 2H, Ar H), 6.76 (d, *J* = 8.8 Hz, 2H, Ar H), 4.38 (s, 2H, CH~2~), 2.97 (s, 6H, 2CH~3~). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 152.81, 151.63, 151.48, 145.69, 136.91, 136.72, 132.93, 129.82, 129.40, 128.10, 122.82, 112.39, 40.63, 40.21. FTIR (KBr, cm^--1^) *ṽ*: 3223, 3066, 2918, 1651, 1583, 1490, 1474, 1366, 1345, 1305, 1183, 1092, 1054, 947, 751, 727, 696, 581, 519, 472. EI-MS: (*M*~wt~: 411.10): *m*/*z* (% rel. int.), 411.13 \[M^+^, (10.64%)\], 126.14 (100%); Anal. Calcd for C~19~H~18~ClN~7~S: C, 55.40; H, 4.40; Cl, 8.61; N, 23.80; S, 7.78. Found: C, 55.73; H, 4.29; N, 24.11; S, 7.69.

#### 4.1.2.20. (*E*)-3-(2-(\[1,1′-Biphenyl\]-4-ylmethylene)hydrazinyl)-6-(4-chlorophenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazine (**5p**) {#sec4.1.2.20}

The titled compound was crystallized from aqueous DMF as yellow crystals (1.21 g, 86.3%); mp 220--223 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 11.01 (s, 1H, NH, D~2~O exchangeable), 8.53 (s, 1H, CH), 8.17 (d, *J* = 8.7 Hz, 2H, Ar H), 7.81--7.75 (m, 4H, Ar H), 7.77--7.69 (m, 2H, Ar H), 7.67 (d, *J* = 8.6 Hz, 2H, Ar H), 7.49 (dd, *J* = 8.5, 6.8 Hz, 2H, Ar H), 7.39 (t, *J* = 7.4 Hz, 1H, Ar H), 4.41 (s, 2H, CH~2~). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 153.19, 151.27, 144.04, 141.15, 139.92, 137.25, 137.02, 134.48, 132.87, 129.86, 129.46, 129.43, 128.19, 127.46, 127.40, 127.06, 40.63. FTIR (KBr, cm^--1^) *ṽ*: 3626, 3151, 3086, 3018, 2984, 2894, 1610, 1590, 1474, 1397, 1312, 1292, 1096, 1087, 1008, 983, 969, 847, 838, 812, 763, 744, 636, 617, 514, 487. EI-MS: (*M*~wt~: 444.09): *m*/*z* (% rel. int.), 444.03 \[M^+^, (26.11%)\], 144.96 (100%); Anal. Calcd for C~23~H~17~ClN~6~S: C, 62.09; H, 3.85; Cl, 7.97; N, 18.89; S, 7.21. Found: C, 62.38; H, 4.03; N, 19.12; S, 7.08.

#### 4.1.2.21. (*E*)-3-(2-(4-(Benzyloxy)benzylidene)hydrazinyl)-6-(4-chlorophenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazine (**5q**) {#sec4.1.2.21}

The titled compound was crystallized from aqueous DMF as yellow crystals (1.35 g, 90.2%); mp 216--220 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 10.79 (s, 1H, NH, D~2~O exchangeable), 8.42 (s, 1H, CH), 8.16 (d, *J* = 8.6 Hz, 2H, Ar H), 7.71--7.58 (m, 4H, Ar H), 7.47 (d, *J* = 7.1 Hz, 2H, Ar H), 7.45--7.37 (m, 2H, Ar H), 7.37--7.31 (m, 1H, Ar H), 7.09 (d, *J* = 8.7 Hz, 2H, Ar H), 5.16 (s, 2H, OCH~2~), 4.39 (s, 2H, CH~2~). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 159.74, 152.99, 151.44, 144.49, 137.31, 137.01, 136.97, 132.89, 129.83, 129.40, 128.91, 128.35, 128.32, 128.19, 128.16, 115.60, 69.80, 40.64. FTIR (KBr, cm^--1^) *ṽ*: 3626, 3216, 3032, 2913, 1654, 1603, 1584, 1471, 1353, 1310, 1246, 1170, 1101, 1006, 972, 858, 832, 745, 714, 653, 625, 534, 458. EI-MS: (*M*~wt~: 474.10): *m*/*z* (% rel. int.), 474.73 \[M^+^, (22.01%)\], 311.27 (100%); Anal. Calcd for C~24~H~19~ClN~6~OS: C, 60.69; H, 4.03; Cl, 7.46; N, 17.69; O, 3.37; S, 6.75. Found: C, 60.97; H, 4.21; N, 17.85; S, 6.89.

#### 4.1.2.22. (*E*)-6-(4-Chlorophenyl)-3-(2-(furan-2-ylmethylene)hydrazinyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazine (**5r**) {#sec4.1.2.22}

The titled compound was crystallized from aqueous DMF as dark yellow crystals (1 g, 88.5%); mp 206--212 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 10.93 (s, 1H, NH, D~2~O exchangeable), 8.44 (s, 1H, CH), 8.15 (d, *J* = 8.6 Hz, 2H, Ar H), 7.80 (d, *J* = 1.8 Hz, 1H, furan H), 7.66 (d, *J* = 8.6 Hz, 2H, Ar H), 6.80 (d, *J* = 3.4 Hz, 1H, furan H), 6.62 (dd, *J* = 3.4, 1.8 Hz, 1H, furan H), 4.40 (s, 2H, CH~2~). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 153.24, 151.15, 150.26, 144.73, 137.31, 137.03, 134.88, 132.74, 129.80, 129.40, 112.49, 112.04, 40.40. FTIR (KBr, cm^--1^) *ṽ*: 3447, 3135, 3070, 2990, 2956, 2883, 2809, 1600, 1591, 1568, 1470, 1338, 1223, 1105, 1078, 935, 884, 851, 757, 594, 565, 472. EI-MS: (*M*~wt~: 358.04): *m*/*z* (% rel. int.), 358.18 \[M^+^, (48.55%)\], 354.59 (100%); Anal. Calcd for C~15~H~11~ClN~6~OS: C, 50.21; H, 3.09; Cl, 9.88; N, 23.42; O, 4.46; S, 8.94. Found: C, 50.49; H, 3.21; N, 23.70; S, 8.86.

#### 4.1.2.23. (*E*)-6-(4-Chlorophenyl)-3-(2-(thiophen-3-ylmethylene)hydrazineyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazine (**5s**) {#sec4.1.2.23}

The titled compound was crystallized from aqueous DMF as yellow crystals (1.03 g, 87.2%); mp 218--221 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 10.80 (s, 1H, NH, D~2~O exchangeable), 8.55 (s, 1H, CH), 8.16 (d, *J* = 8.3 Hz, 2H, Ar H), 7.81 (t, *J* = 2.7 Hz, 1H, thiophene H), 7.66 (d, *J* = 8.6 Hz, 2H, Ar H), 7.62 (dd, *J* = 5.3, 2.9 Hz, 1H, thiophene H), 7.45 (d, *J* = 4.8 Hz, 1H, thiophene H), 4.39 (s, 2H, CH~2~). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 152.93, 151.54, 140.64, 138.58, 137.02, 136.92, 132.92, 129.81, 129.41, 127.80, 126.38, 124.98, 40.21. FTIR (KBr, cm^--1^) *ṽ*: 3626, 3448, 3097, 2915, 1734, 1651, 1623, 1560, 1485, 1408, 1315, 1238, 1107, 1088, 1070, 949, 810, 769, 784, 726, 689, 565, 444. EI-MS: (*M*~wt~: 374.01): *m*/*z* (% rel. int.), 374.95 \[M^+^, (16.22%)\], 45.07 (100%); Anal. Calcd for C~15~H~11~ClN~6~S~2~: C, 48.06; H, 2.96; Cl, 9.46; N, 22.42; S, 17.10. Found: C, 48.32; H, 3.09; N, 22.71; S, 17.04.

#### 4.1.2.24. (*E*)-3-(2-((1*H*-Indol-3-yl)methylene)hydrazineyl)-6-(4-chlorophenyl)-7*H*-\[1,2,4\]triazolo\[3,4-*b*\]\[1,3,4\]thiadiazine (**5t**) {#sec4.1.2.24}

The titled compound was crystallized from aqueous DMF as dark yellow crystals (1.13 g, 87.9%); mp 206--212 °C; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 11.46 (s, 1H, NH~1″~, D~2~O exchangeable), 10.49 (s, 1H, NH, D~2~O exchangeable), 8.58 (s, 1H, CH), 8.32--8.24 (m, 1H, indole H), 8.16 (d, *J* = 8.6 Hz, 2H, Ar H), 7.73 (d, *J* = 2.6 Hz, 1H, indole H), 7.65 (d, *J* = 8.6 Hz, 2H, Ar H), 7.43 (d, *J* = 8.1 Hz, 1H, indole H), 7.18 (ddd, *J* = 8.1, 7.0, 1.3 Hz, 1H, indole H), 7.05 (t, *J* = 7.2 Hz, 1H, indole H), 4.40 (s, 2H, CH~2~). ^13^C NMR (101 MHz, DMSO-*d*~6~): δ 152.77, 152.00, 142.26, 137.43, 136.85, 136.68, 133.02, 129.82, 129.39, 129.17, 124.78, 122.89, 122.54, 120.49, 112.46, 112.11, 40.62. FTIR (KBr, cm^--1^) *ṽ*: 3626, 3421, 3170, 3010, 2922, 1651, 1508, 1479, 1390, 1339, 1249, 1091, 1057, 814, 751, 608, 518, 472. EI-MS: (*M*~wt~: 407.07): *m*/*z* (% rel. int.), 407.80 \[M^+^, (51.57%)\], 116.79 (100%); Anal. Calcd for C~19~H~14~ClN~7~S: C, 55.95; H, 3.46; Cl, 8.69; N, 24.04; S, 7.86. Found: C, 56.12; H, 3.75; N, 24.27; S, 7.90.

4.2. Biological Evaluation {#sec4.2}
--------------------------

### 4.2.1. In Vitro Antiproliferative Activity against NCI-60 Cell Lines {#sec4.2.1}

The synthesized compounds were screened for their cytotoxic activity against 60 cell lines by the National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA^[@ref74]^ under the Developmental Therapeutics Program (DTP) (<https://dtp.cancer.gov/compsub/>) for NCI-60 human tumor cell lines screen. The operation of this screen utilizes 60 different human tumor cell lines, representing leukemia, NSCLC, colon, CNS, ovarian, renal, prostate, breast cancers, and melanoma. The compounds are initially screened at 10 μM concentration for measuring the cell growth percent. The data of the single dose treatment are represented as mean graph ([Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c01829/suppl_file/ao0c01829_si_001.pdf)).

### 4.2.2. In Vitro Kinase Screening {#sec4.2.2}

Compound **5l** was screened against the 16 kinases for kinase inhibition percent determination in Thermo Fisher Scientific corporation, Madison, WI, USA (<https://www.thermofisher.com/eg/en/home.html>), under the SelecScreen program. The assay of the compounds is carried out according to the manufacturer's protocol with the ATP concentration at the km (Michaelis constant) of each kinase, except for MAPK8, where ATP concentration was 100 μM.

### 4.2.3. In Vitro GSK-3β IC~50~ Determination {#sec4.2.3}

The IC~50~ of **5l** against GSK-3β was determined using the Kinase-Glo Max Assay kit (Promega\#V6071) of BPS Biosciences corporation, San Diego, CA, USA ([www.bpsbioscience.com](www.bpsbioscience.com)) (catalog \#79700). The following concentrations were prepared for the test compounds: 10, 1, 0.1, and 0.01 μM. The reaction mixture and the test compounds concentrations were prepared according to the manufacturer's protocol. The Kinase-Glo (Promega) was used as a detection reagent, and luminescence was measured using a Bio Tek *Synergy* 2 microplate reader. Measures of the control and sample were carried out in duplicates. The reference GSK-3β inhibitor used was **AR-A014418**.^[@ref79]^

### 4.2.4. Annexin V/PI Staining Apoptosis Assay {#sec4.2.4}

Apoptosis and cell cycle analysis studies were performed at Cell Culture Unit, Vacsera, Cairo, Egypt. The PC-3 cells were treated with **5l** at the IC~50~ concentration (0.883 μM) for 48 h and cultured in six well plates. Annexin V-FITC Apoptosis Detection Kit (BioVision, CA, USA) was used to stain the cells with 5 μL propidium iodide (PI) and 5 μL Annexin V-FITC after being fixed for 0.5 h in cold ethanol. The FACScan flow cytometer (Beckman Coulter, CA, USA) was used for the cells' analysis with a 15 min period of dark and room temperature treatment. Apoptosis was evaluated in terms of the fluorescein isothiocyanate (FITC)-positive cells.

### 4.2.5. Cell Cycle Analysis {#sec4.2.5}

PC-3 cells were treated with 0.883 μM of compound **5l**. **5l**-treated PC-3 cells were trypsinized, washed with phosphate buffered saline (PBS), resuspended in cold methanol, and kept overnight at 4 °C, 48 h after treatment. The cells were then resuspended in sodium citrate buffer with RNase and incubated at 37 °C for 30 min. The cells were then centrifugated and collected to be resuspended in PBS and filtered. FACSCalibur Flow Cytometer (BD Biosciences, San Jose, CA, USA) was then used for cell cycle analysis.

### 4.2.6. Caspase-3 Determination in PC-3 Cells Treated with **5l** {#sec4.2.6}

Caspase-3 (active) levels were measured in the cell lysates using the human caspase-3 ELISA kit obtained from Invitrogen (catalog \#KHO1091, CA, USA), according to the manufacturer's instructions.

### 4.2.7. Statistical Analysis {#sec4.2.7}

Statistical analysis was performed using the Student's *t*-test for unpaired data. The values were acquired from three experiments conducted independently in triplicates, and data were represented as mean ± standard deviation (S.D.). GraphPad Prism, version 5.01 (GraphPad Software, CA, USA), was used for data analysis and figures generation. *p* \< 0.05 was set as the statistical significance level.

4.3. Molecular Modeling {#sec4.3}
-----------------------

### 4.3.1. Ligand-Based Target Fishing {#sec4.3.1}

LBTF was carried out using 3D similarity searching between a query compound and a target-annotated compound database. Compound **5l**, the most active compound in NCI-60 cell line screening, was used as a query, while the binding database ([www.bindingdb.org](www.bindingdb.org)) (downloaded on June 6th 2018, 1.4 M compounds) was used as the database.^[@ref75]−[@ref77]^ First, a multiconformer file of the binding database was generated using in-house multithreaded OMEGA python script written using the OMEGA Toolkit.^[@ref84]^ 3D similarity was then calculated between the query molecule and every conformer in the BindingDB multiconformer file. The FastROCS shape comparison software toolkit,^[@ref78]^ the GPU version of ROCS (Rapid Overlay of Chemical Structures) software,^[@ref85]^ was used for the 3D similarity searching. ROCS target fishing ability was validated in a target fishing protocol for the determination of polypharmacology of selected drugs.^[@ref86]^ The similarity measurement in FastROCS depends on two criteria, shape similarity, and color similarity. According to ROCS philosophy, shape is the shape of the molecule described using a Gaussian function which describes the molecule's volume. Color is the functional group of the molecule. Each similarity is measured by the Tanimoto coefficient which has a value of \[0, 1\]; 0 means totally dissimilar, and 1 means totally similar (the same molecule). Combining both shape and color Tanimoto coefficients gives the Tanimoto combo coefficient with a value of \[0, 2\]. The results were ranked with the Tanimoto combo in a descending order.

### 4.3.2. Molecular Docking {#sec4.3.2}

The ligands were sketched using MarvinSketch and energy-minimized using OpenBabel software implementing the steepest descent algorithm for a convergence criterion of 10^--6^ kcal/mol/Å and 10,000 iterations using MMFF94s (Merck molecular force field static variant) for energy evaluation at each step.

The GSK-3β protein structure (PDB ID: 1Q5K) was downloaded from the RCSB Protein Data Bank (<http://www.rcsb.org/>).^[@ref87],[@ref88]^ Protein structure was prepared using Make Receptor utility of the OEDOCKING 3.4.0.2 module of OpenEye software.^[@ref81]^ The box of search area was determined around **AR-A014418** co-crystallized ligand (PDB ID: TMU) with the default dimensions, followed by detection of shape potential of the binding site. Ligands were then prepared by multiconformer file generation using OMEGA 3.1.2.2 OpenEye software.^[@ref89],[@ref90]^ Docking was carried out by FRED and HYBRID applications of the OEDOCKING 3.4.0.2 module of OpenEye software.^[@ref81]−[@ref83]^ DockRMSD was used to measure docking rmsd.^[@ref91]^ All protein--ligand figures generation was carried out using UCSF Chimera visualization software.^[@ref92]^

### 4.3.3. Molecular Dynamics {#sec4.3.3}

Simulation system preparation was carried out using VMD 1.9.3 software.^[@ref93]^ The protein structure was first cleared of any nonprotein atoms (water, ions, or ligands); then, the topology file for the protein was generated using the psfgen 1.6.4 package implemented through VMD. The topology file of the ligands was generated by SwissParam web server.^[@ref94]^ The protein--ligand complex was constructed manually by incorporating both topology files, which is then solvated in the TIP3P water model, forming a box of 14 Å margin in every direction of the protein atoms using the VMD solvate 1.7 package, followed by charge neutralization with Na^+^Cl^--^ ions using VMD autoionize 1.4 package, ending up with systems of 72,000 atoms, approximately. MD calculations were carried out using NAMD 2.13 software.^[@ref95]^ 100,000 minimization steps were carried out using the coupled conjugate gradient and line search algorithms of NAMD, followed by the 20 ns *NPT* equilibration phase. Protein parameters were provided by the CHARMM36 force field^[@ref96]−[@ref98]^ (July 2017 release), while ligand parameters were generated using SwissParam. The dynamics configuration file was set to neglect 1--2 and 1--3 atom interactions, and fully consider 1--4 interactions. Pair list distance for calculating van der Waals and electrostatic interactions were set to 13.5 Å and restarted every integration cycle, while calculated within 12, with 10 Å switch distance for function smoothing. Velocity and position were calculated using the velocity Verlet integration method, while electrostatics were calculated using the particle mesh Ewald sum method,^[@ref99]^ all with a time step of 2 fs. The frequency of calculating the nonbonded and electrostatic interactions was 2 fs (1 time step). Langevin dynamics was used for keeping the system temperature constant at 310 K (37 °C) with 1 ps^--^ damping coefficient applied only to heavy atoms. The Langevin piston with 200 fs oscillation period and 50 fs damping period was used to keep the pressure constant at 1 atm (1.01325 bar), coupled with the Nose--Hoover method^[@ref100]^ to control barostat fluctuations. The dynamics simulation analysis was carried out using *ProDy* python package^[@ref101],[@ref102]^ and VMD rmsd trajectory tool. All analysis charts were constructed using Matplotlib 3.0.2 python plotting library.^[@ref103]^

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acsomega.0c01829](https://pubs.acs.org/doi/10.1021/acsomega.0c01829?goto=supporting-info).Copies of NMR spectra for compounds **5a--t**, kinase inhibitors retrieved from target fishing, and NCI screening mean graph example ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c01829/suppl_file/ao0c01829_si_001.pdf))
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